Structural Biology Solutions Catered To Your Project Needs

Receive purified proteins and structural information to support assays, structure-based drug design, high throughput screening, in vivo studies, biopharmaceutical projects, diagnostic applications, biophysics, or fragment-based screening. Tackling challenging protein targets with extensive knowledge and expertise, Sygnature Discovery is likely to find solutions to protein science and structural biology problems, guiding and advising every step of the way.

X-ray Crystallography

Benefit from decades of experience in solving X-ray crystal structures across a wide range of protein classes. Proven expertise includes de-novo protein structure determination of challenging targets, rapid turnaround protein-ligand complexes, and driving X-ray based FBLG projects.

NMR Spectroscopy

Comprehensive NMR services include protein characterisation, protein structure determination, and ligand interaction studies. Significant experience in producing high-quality labelled (15N, 13C, and 2H) proteins and providing residue-specific labelling when needed.

Structure of Membrane Proteins

A dedicated membrane protein team generates high-quality protein in-house to improve the chances of delivering both X-ray and Cryo-EM structures of these challenging protein targets.

Cryo-EM

Support for all stages of a single particle cryo-EM project, from construct design to refined structure. Protein quality is crucial for structure determination by cryo-EM, especially for the most interesting and hardest to project targets. Extensive experience includes producing challenging proteins, such as membrane proteins.

Protein Purification and Analysis

Tailored proteins designed to meet individuals needs, from initial construct design through to QC and analysis by Mass Spectrometry, Fida, SPR, an SEC-MALS. Expertise extends to challenging proteins with significant membrane protein experience.

Fragment Based Drug Discovery

Two options for FBDD: 1. X-ray crystallography structure with fragment hits from a primary screen such as SPR or ASMS. 2. Full fragment screening by X-ray crystallography. Choose from an in-house, fully curated fragment library or other libraries if required.

Delivering for our customers - a proven track record

  • 48 pre-clinical candidates delivered
  • 27 already progressed to clinical trials (>50%)
  • Sygnature Discovery co-inventors named on >170 client patent applications
Performance graph only (with atom filigrane)-1

Discover your next project's potential